Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Keymed Biosciences has a Cash Ratio of 3.97. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for Keymed Biosciences's Cash Ratio or its related term are showing as below:
FRA:64Z'
s Cash Ratio Range Over the Past 10 Years
Min: 2.3 Med: 6.97 Max: 31.45
Current: 3.95
During the past 7 years, Keymed Biosciences's highest Cash Ratio was 31.45. The lowest was 2.30. And the median was 6.97.
FRA:64Z's Cash Ratio is ranked better than 57.39% of 1380
companies
in the Biotechnology industry
Industry Median: 2.96
vs FRA:64Z: 3.95
Keymed Biosciences (FRA:64Z) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Keymed Biosciences Cash Ratio Related Terms
Keymed Biosciences Cash Ratio Historical Data
* Premium members only.
The historical data trend for Keymed Biosciences's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:64Z vs VRTX, REGN, MRNA: Cash Ratio Comparison
For the Biotechnology subindustry, Keymed Biosciences's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Keymed Biosciences Cash Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Keymed Biosciences's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Keymed Biosciences's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Keymed Biosciences (FRA:64Z) has a Cash Ratio of 3.97 as of Jun. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Keymed Biosciences and its competitors. This is 43% below median its historical median of 6.97. Over the past decade, Keymed Biosciences' Cash Ratio has ranged from 2.30 to 31.45. According to the industry distribution chart, Keymed Biosciences ranks #588 out of 1380 companies in the Biotechnology industry, placing it in the top 42.6%.
Is Keymed Biosciences' Cash Ratio too high?
Keymed Biosciences' current Cash Ratio of 3.97 is 43% below median its 10-year median of 6.97. Over the past 10 years, this metric has ranged from a low of 2.30 to a high of 31.45. The Biotechnology industry median Cash Ratio is 2.96. Keymed Biosciences' value of 3.97 is 34.1% above this industry median. Based on the distribution chart, Keymed Biosciences ranks #588 out of 1380 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Keymed Biosciences has a GF Score™ of 49/100, reflecting its overall financial health beyond just this single metric.
How does Keymed Biosciences' Cash Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Keymed Biosciences ranks #588 out of 1380 companies for Cash Ratio. This puts Keymed Biosciences in the upper half of its industry. The industry median Cash Ratio is 2.96. Keymed Biosciences' value of 3.97 is 34.1% above this benchmark. Historically, Keymed Biosciences' own Cash Ratio has ranged from 2.30 to 31.45 over the past decade. While the company's 10-year median is 6.97 vs. the industry median of 2.96, Keymed Biosciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Biotechnology company?
The median Cash Ratio among Biotechnology companies is 2.96, based on 1,380 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Keymed Biosciences's current Cash Ratio of 3.97 is 34.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Keymed Biosciences and its competitors. For the Biotechnology industry, the median Cash Ratio is 2.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Keymed Biosciences's current Cash Ratio is 3.97, which is 43% below median its own 10-year median of 6.97. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Keymed Biosciences stock overvalued right now?
Keymed Biosciences (FRA:64Z) has a current Cash Ratio of 3.97. The stock's GF Value™ is €16.65, compared to a current price of €7.90 — trading 52.6% below its estimated fair value. The current Cash Ratio is 3.97, which is 43% below median its 10-year median of 6.97 and 34.1% above the Biotechnology industry median of 2.96. Keymed Biosciences' overall GF Score™ is 49/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Keymed Biosciences (FRA:64Z), the current Cash Ratio is 3.97 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Keymed Biosciences (FRA:64Z) Overvalued in 2026?
Based on GuruFocus' analysis, Keymed Biosciences stock appears to be undervalued.
The current stock price of €7.90 is trading 52.6% below its estimated GF Value™ of €16.65.
Key valuation signals for FRA:64Z:
Cash Ratio: 3.97 (43% below median its 10-year median of 6.97)
GF Value™: €16.65 vs. price of €7.90 (52.6% below fair value)
Industry Position: 34.1% above the Biotechnology median (#588 of 1380)
No single metric tells the full story. See the FRA:64Z stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Keymed Biosciences Inc is a biotechnology company with multiple clinical-stage assets. The company is focused on the in-house discovery and development of biological therapies that address large underserved medical needs in the autoimmune and oncology therapeutic areas. Its clinical-stage drug candidates include CM310, CM326, CM313, and CM336 among others. The company is engaged in biopharmaceutical research and development, which is regarded as a single reportable segment. Geographically, it generates a majority of its revenue from overseas markets and the rest from Mainland China.
49GF Score
Get the complete analysis for FRA:64Z
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:64Z has been successfully added to your 
